International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(1):1-12.

Meta-Analysis of Gene Expression Profiles in Acute Promyelocytic Leukemia Reveals Involved Pathways
Mahdi Jalili, Ali Salehzadeh-Yazdi, Saeed Mohammadi, Marjan Yaghmaie, Ardeshir Ghavamzadeh, Kamran Alimoghaddam


Background: Acute promyelocytic leukemia (APL) is a unique subtype of acute leukemia. APL is a curable disease; however, drug resistance, early mortality, disease relapse and treatment-related complications remain challenges in APL patient management. One issue underlying these challenges is that the molecular mechanisms of the disease are not sufficiently understood.

Materials and Methods: In this study, we performed a meta-analysis of gene expression profiles derived from microarray experiments and explored the background of disease by functional and pathway analysis.

Results: Our analysis revealed a gene signature with 406 genes that are up or down-regulated in APL. The pathway analysis determined that MAPK pathway and its involved elements such as JUN gene and AP-1 play important roles in APL pathogenesis along with insulin-like growth factor–binding protein-7.

Conclusions: The results of this meta-analysis could be useful for developing more effective therapy strategies and new targets for diagnosis and drugs.


Acute promyelocytic leukemia; Gene expression profile; Meta-Analysis; Functional analysis

Full Text:



Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003; 17(8):1454-63.

Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13):1295-305.

Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29(20):2753-7.

Lo-Coco F, Hasan SK. Understanding the molecular

pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014; 27(1):3-9.

Rego EM, He LZ, Warrell RP JR, et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A. 2000; 97(18):10173-8.

.6. Qiu JJ, Lu X, Zeisig BB, et al. Leukemic transformation by the APL fusion protein PRKAR1A-RAR{alpha} critically depends on recruitment of RXR{alpha}. Blood. 2010; 115(3):643-52.

Yamamoto Y, Tsuzuki S, Tsuzuki M, et al. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood. 2010; 116(20):4274-83.

Rao A, Manyam G, Rao G, et al. Integrative Analysis of mRNA, microRNA, and Protein Correlates of Relative Cerebral Blood Volume Values in GBM Reveals the Role for Modulators of Angiogenesis and Tumor Proliferation. Cancer Inform. 2016; 15:29-33.

Zeng Y, Zhang L, Zhu W, et al. Quantitative proteomics and integrative network analysis identified novel genes and pathways related to osteoporosis. J Proteomics. 2016; 142:45-52.

Sun YV, Hu Y-J. Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases. Adv Genet. 2016; 93:147-90.

Xia J, Fjell CD, Mayer ML, et al. INMEX—a web-based tool for integrative meta-analysis of expression data. 2013; 41(Web Server issue):W63-70.

Ramasamy A, Mondry A, Holmes CC, et al. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med. 2008; 5(9):e184.

Cheung AM, Chow HC, Liang R, et al. A comparative study of bone marrow and peripheral blood CD34+ myeloblasts in acute myeloid leukaemia. Br J Haematol. 2009; 144(4):484-91.

Gautier L, Cope L, Bolstad BM, et al. Affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15.

Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23(14):1846-7.

Kauffmann A, Gentleman R, Huber W. ArrayQuality Metrics--a bioconductor package for quality assessment of microarray data. Bioinformatics. 2009; 25(3):415-6.

Carter SL, Eklund AC, Mecham BH, et al. Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics. 2005; 6(1):107.

Maglott D, Ostell J, Pruitt KD, et al. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2011; 39 (Database issue):D52-7.

Chang LC, Lin HM, Sibille E, et al. Meta-analysis methods for combining multiple expression profiles: comparisons, statistical characterization and an application guideline. BMC Bioinformatics. 2013; 14(1):368.

Hong F, Breitling R. A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics. 2008; 24(3):374-82.

Tseng GC, Ghosh D, Feingold E. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012; 40(9):3785-99.

Breitling R, Armengaud P, Amtmann A, et al. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004; 573(1-3):83-92.

Hong F, Breitling R, McEntee CW, et al. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics. 2006; 22(22):2825-7.

Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57.

Ashburner M, Ball CA, Blake JA, et al. Gene Ontology: tool for the unification of biology. Nat Genet. 2000; 25(1):25-9.

Croft D, Mundo AF, Haw R, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014; 42 (Database issue):D472-7.

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50.

Vazquez A, Flammini A, Maritan A, et al. Global protein function prediction from protein-protein interaction networks. Nat Biotechnol.2003; 21(6):697-700.

Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res.2015; 43(Database issue):D447-52.

Assenov Y, Ramírez F, Schelhorn SE, et al. Computing topological parameters of biological networks. Bioinformatics. 2008; 24(2):282-4.

Minguez P, Gotz S, Montaner D, et al. SNOW, a web-based tool for the statistical analysis of protein-protein interaction networks. Nucleic Acids Res. 2009; 37(Web Server issue):W109-14.

Glaab E, Baudot A, Krasnogor N, et al. EnrichNet: network-based gene set enrichment analysis. Bioinformatics. 2012; 28(18):i451-i7.

Casorelli I, Tenedini E, Tagliafico E, et al. Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes. Leukemia. 2006; 20(11):1978-88.

Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002; 4(5):E131-E6.

Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003; 3(11):859-68.

Eychène A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer. 2008;8(9):683-93.

Meng Q, Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell. 2011; 2(11):889-98.

Andrecht S, Kolbus A, Hartenstein B, et al. Cell cycle promoting activity of JunB through cyclin A activation. J Biol Chem. 2002; 277(39):35961-8.

Bakiri L, Lallemand D, Bossy‐Wetzel E, et al. Cell cycle‐dependent variations in c‐Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000; 19(9):2056-68.

Passegué E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16INK4a expression. EMBO J. 2000; 19(12):2969-79.

Kovary K, Bravo R. The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol. 1991; 11(9):4466-72.

Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000; 103(2):239-52.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357(9255):539-45.

Kagoya Y, Yoshimi A, Kataoka K, et al. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. J Clin Invest. 2014; 124(2):528-42.

Katsoulidis E, Li Y, Yoon P, et al. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res. 2005; 65(19):9029-37.

Navas TA, Mohindru M, Estes M, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006; 108(13):4170-7.

Chen Y, Miao ZH, Zhao WM, et al. The p53 pathway is synergized by p38 MAPK signaling to mediate 11, 11′-dideoxyverticillin-induced G 2/M arrest. FEBS Lett. 2005; 579(17):3683-90.

Marderosian M, Sharma A, Funk AP, et al. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene. 2006; 25(47):6277-90.

Pedraza‐Alva G, Koulnis M, Charland C, et al. Activation of p38 MAP kinase by DNA double‐strand breaks in V (D) J recombination induces a G2/M cell cycle checkpoint. EMBO J. 2006; 25(4):763-73.

Shi Y, Sharma A, Wu H, et al. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK-and ERK-dependent pathway. J Biol Chem. 2005; 280(12):10964-73.

Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006; 12(4):446-51.

Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood. 2007; 110(8):3056-63.

Alsayed Y, Uddin S, Mahmud N, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem. 2001; 276(6):4012-9.

Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-β on normal hematopoiesis. J Biol Chem. 2002; 277(10):7726-35.

Geh E, Meng Q, Mongan M, et al. Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) integrates developmental signals for eyelid closure. Proc Natl Acad Sci U S A. 2011; 108(42):17349-54.

Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012; 12(3):159-69.

Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23(6):824-54.

Verhagen HJ, de Leeuw D, Roemer MG, et al. IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death Dise. 2014; 5(6):e1300.

Costello RT, Mallet F, Sainty D, et al. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol.1998; 28(1):90-103.

Tamura H, Dan K, Tamada K, et al. Expression of functional B7-H2 and B7. 2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res. 2005; 11(16):5708-17.

Hamed N, Farahat N, Sorady ME, et al. Clinical significance of soluble CD86 levels in patients with acute myelogenous leukemia. Alexandria Journal of Medicine. 2011; 47(1):25-30.

Wampfler J, Federzoni EA, Torbett BE, et al. The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation. Leuk Res. 2016; 41:96-102.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.